OFF-X NEWS

BIOINFOGATE’S OFF-X PROVIDES A DEDICATED “COVID-19” SECTION

The COVID-19 section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.

To complement the efforts being made worldwide in the fight against COVID-19, Bioinfogate is pleased to announce that they are providing complimentary access to a dedicated “COVID-19” section in OFF-X, the translational safety information portal. This section features the latest safety alerts related to drugs being investigated as potential treatments, vaccinations or supportive care.

Updated as soon as new information becomes available, the COVID-19 section provides a compilation of safety alerts derived from recent publications related to COVID-19 as well as previous OFF-X content that may be of interest.

Dr Josep Prous, Jr, Executive Director at Bioinfogate commented: “We are very pleased to be able to contribute to the global efforts being made to tackle this pandemic, by helping optimize pharmaceutical R&D and minimize patient risks in clinical trials and beyond”.

The COVID-19 report can be accessed via the OFF-X home page, from the Selected Daily Alerts section. Content can be sorted and/or filtered by target, drug of interest or date. Clicking on any alert jumps to OFF-X and the full alert details.

About Bioinfogate

Bioinfogate is a forward thinking, private company working to solve unmet medical needs. Our innovative data science products support the discovery and development of better and safer drugs. We are committed to building industry-leading solutions and identifying / investing in emerging projects that align with our core business in the life sciences and data analytics.

Our passion and capabilities stem from more than 60 years of experience creating and managing biomedical knowledge, first at Prous Science (1958-2007), acquired by Thomson Reuters in 2007 (now Clarivate Analytics), and then at Prous Institute for Biomedical Research. Bioinfogate is the latest initiative within the Prous family group of companies embracing a long tradition and expertise in scientific knowledge management.

CLARIVATE ACQUIRES BIOINFOGATE, REINFORCING POSITION AS PREMIER PROVIDER OF END-TO-END RESEARCH INTELLIGENCE SOLUTIONS FOR LIFE SCIENCES

Expanding and integrating drug toxicity data and translational safety intelligence from OFF-X into all aspects of the life science cycle, allowing customers to make more informed decisions

Aug 04 ,2021

FDA AND BIOINFOGATE AGREE TO EXTEND FOR 2 ADDITIONAL YEARS THE MATERIAL TRANSFER AGREEMENT (MTA) TO PROVIDE AGENCY-WIDE ACCESS TO THE OFF-X TRANSLATIONAL SAFETY INTELLIGENCE PORTAL

The agreement aims to evaluate new approaches to enhance safety assessments of human pharmaceuticals and their associated molecular targets, supporting the FDA’s mission of protecting public health.

May 12 ,2021

EXTERNAL VALIDATION OF BIOINFOGATE’S OFF-X FAERS CURATION PROCESS & STATISTICAL SIGNAL EXTRACTION TO BE SUPPORTED BY INTAGE HEALTHCARE’S CZEEKV PRO

Bioinfogate has established an agreement with INTAGE Healthcare to perform an external validation of their methodologies to curate information from FAERS and extract safety signals using well-established statistical methods with the CzeekV Pro database system.

Mar 22 ,2021

BIOINFOGATE’S OFF-X REACHES ONE MILLION SAFETY ALERTS

OFF-X has become the largest translational safety and toxicity intelligence portal for drugs and targets of pharmacological interest.

Jan 18 ,2021

NEW COLLABORATION BETWEEN BIOINFOGATE AND INTAGE HEALTHCARE TO DELIVER JAPANESE PHARMACOVIGILANCE INSIGHTS IN OFF-X

Bioinfogate will integrate JADER case reports and pharmacovigilance signals into OFF-X to complement its unique translational view of safety intelligence.

Oct 15 ,2020